# A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

> **NCT05670925** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 46 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Camrelizumab plus Famitinib with/without nab-Palitaxel

## Key facts

- **NCT ID:** NCT05670925
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2023-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05670925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05670925, "A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05670925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*